NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 3 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $81,000 | +189.3% | 152,900 | +267.9% | 0.00% | – |
| Q2 2020 | $28,000 | +7.7% | 41,557 | -8.2% | 0.00% | – |
| Q1 2020 | $26,000 | -62.9% | 45,245 | -14.4% | 0.00% | – |
| Q4 2019 | $70,000 | -33.3% | 52,842 | +0.3% | 0.00% | – |
| Q3 2019 | $105,000 | -17.3% | 52,672 | +0.8% | 0.00% | – |
| Q2 2019 | $127,000 | +182.2% | 52,272 | +180.8% | 0.00% | – |
| Q1 2019 | $45,000 | +200.0% | 18,616 | +82.2% | 0.00% | – |
| Q4 2018 | $15,000 | – | 10,220 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
| Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
| IFP Advisors, Inc | 0 | $0 | 0.00% |